Literature DB >> 23506251

Flow cytometric assessment of circulating platelet and erythrocytes microparticles in young thalassemia major patients: relation to pulmonary hypertension and aortic wall stiffness.

Azza A G Tantawy1, Amira A M Adly, Eman A R Ismail, Nevin M Habeeb.   

Abstract

Heart disease is the leading cause of mortality and morbidity in β-thalassemia major (β-TM). Aggregability of abnormal red cells and membrane-derived microparticles (MPs) stemming from activated platelets and erythrocytes are responsible for thrombotic risk. We measured platelet and erythrocyte MPs (PMPs and ErMPs) in 60 young β-TM patients compared with 40 age- and sex-matched healthy controls and assessed their relation to clinicopathological characteristics and aortic elastic properties. Patients were studied stressing on transfusion history, splenectomy, thrombotic events, chelation therapy, hematological and coagulation profiles, flow cytometric measurement of PMPs (CD41b(+) ) and ErMPs (glycophorin A(+) ) as well as echocardiographic assessment of aortic elastic properties. Aortic stiffness index and pulmonary artery pressure were significantly higher, whereas aortic strain and distensibility were lower in TM patients than controls (P < 0.001). Both PMPs and ErMPs were significantly elevated in TM patients compared with controls, particularly patients with risk of pulmonary hypertension, history of thrombosis, splenectomy or serum ferritin >2500 μg/L (P < 0.001). Compliant patients on chelation therapy had lower MPs levels than non-compliant patients (P < 0.001). PMPs and ErMPs were positively correlated to markers of hemolysis, serum ferritin, D-dimer, vWF Ag, and aortic stiffness, whereas negatively correlated to hemoglobin level and aortic distensibility (P < 0.05). We suggest that increased MPs may be implicated in vascular dysfunction, pulmonary hypertension risk, and aortic wall stiffness observed in thalassemia patients. Their quantification could provide utility for early detection of cardiovascular abnormalities and monitoring the biological efficacy of chelation therapy.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23506251     DOI: 10.1111/ejh.12108

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  12 in total

1.  Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Authors:  Claudia R Morris; Hae-Young Kim; Elizabeth S Klings; John Wood; John B Porter; Felicia Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Kathryn Hassell; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Sandra Larkin; Jung H Suh; Elliott P Vichinsky; Frans A Kuypers
Journal:  Br J Haematol       Date:  2015-04-24       Impact factor: 6.998

2.  Response to "efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18.

Authors:  Elizabeth S Klings; Elliott P Vichinsky; Claudia R Morris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

3.  CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility.

Authors:  Hisham A E Awad; Azza A G Tantawy; Rania A El-Farrash; Eman A Ismail; Noha M Youssif
Journal:  Blood Transfus       Date:  2013-11-15       Impact factor: 3.443

4.  Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major.

Authors:  Amira Abdel Moneam Adly; Nayera Hazaa Khalil ElSherif; Eman Abdel Rahman Ismail; Yosra Abdelzaher Ibrahim; Gamal Niazi; Sara Hamed Elmetwally
Journal:  Redox Rep       Date:  2017-03-13       Impact factor: 4.412

5.  Platelet haemostatic properties in β-thalassaemia: the effect of blood transfusion.

Authors:  Alice Trinchero; Marina Marchetti; Cinzia Giaccherini; Carmen J Tartari; Laura Russo; Anna Falanga
Journal:  Blood Transfus       Date:  2016-10-04       Impact factor: 3.443

6.  Pulmonary hypertension in well-transfused thalassemia major patients.

Authors:  Antonella Meloni; Jon Detterich; Alessia Pepe; Paul Harmatz; Tom D Coates; John C Wood
Journal:  Blood Cells Mol Dis       Date:  2014-11-24       Impact factor: 3.039

7.  MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3.

Authors:  Hongwei Liang; Xin Yan; Yi Pan; Yongsheng Wang; Nan Wang; Limin Li; Yuan Liu; Xi Chen; Chen-Yu Zhang; Hongwei Gu; Ke Zen
Journal:  Mol Cancer       Date:  2015-03-11       Impact factor: 27.401

8.  Extracellular Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional Status and Ineffective Erythropoiesis.

Authors:  Carina Levin; Ariel Koren; Annie Rebibo-Sabbah; Naama Koifman; Benjamin Brenner; Anat Aharon
Journal:  Front Physiol       Date:  2018-08-30       Impact factor: 4.566

9.  Microparticles from β-thalassaemia/HbE patients induce endothelial cell dysfunction.

Authors:  Wasinee Kheansaard; Kunwadee Phongpao; Kittiphong Paiboonsukwong; Kovit Pattanapanyasat; Pornthip Chaichompoo; Saovaros Svasti
Journal:  Sci Rep       Date:  2018-08-29       Impact factor: 4.379

Review 10.  Biomarkers for pediatric pulmonary arterial hypertension - a call to collaborate.

Authors:  Kelley L Colvin; Melanie J Dufva; Ryan P Delaney; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager
Journal:  Front Pediatr       Date:  2014-02-03       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.